Time to FVC 10% Decline | Time to DLCO 15% Decline | Mortality | ||||
---|---|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | P | HR (95% CI) | p | |
IL-6 | 1.34 (1.12–1.6) | 0.001 | 1.14 (0.96–1.36) | 0.13 | 1.32 (1.08–1.62) | 0.007 |
Sex | 1.19 (0.74–1.96) | 0.46 | 1.59 (1.02–2.49) | 0.04 | 1.36 (0.77–2.41) | 0.3 |
Age | 1.01 (0.99–1.02) | 0.48 | 1.02 (1.00–1.04) | 0.02 | 1.03 (1.00–1.05) | 0.004 |
Smoking | 1.06 (0.77–1.46) | 0.66 | 1.32 (0.98–1.8) | 0.07 | 1.14 (0.77–1.68) | 0.5 |
dcSSc | 1.59 (1.03–2.43) | 0.04 | 1.70 (1.11–2.59) | 0.01 | 1.26 (0.74–2.13) | 0.4 |
PH | 2.43 (1.33–4.44) | 0.004 | 2.1 (1.13–3.9) | 0.02 | 3.85 (2.11–7.03) | < 0.0001 |
DTPA | 0.98 (0.97–0.99) | 0.004 | 0.99 (0.97–1.00) | 0.03 | 0.98 (0.96–1.00) | 0.06 |
FEV1, % | 0.98 (0.97–0.99) | 0.03 | 0.99 (0.98–1.00) | 0.52 | 0.98 (0.97–0.99) | 0.003 |
FVC, % | 0.98 (0.97–0.99) | 0.02 | 0.99 (0.98–1.00) | 0.43 | 0.99 (0.97–0.99) | 0.005 |
TLC, % | 0.98 (0.96–0.99) | 0.02 | 0.99 (0.98–1.01) | 0.5 | 0.98 (0.96–1.00) | 0.01 |
DLCO, % | 0.98 (0.97–0.99) | 0.007 | 0.99 (0.98–1.00) | 0.06 | 0.96 (0.94–0.97) | < 0.0001 |
KCO, % | 0.98 (0.97–1.01) | 0.19 | 0.98 (0.97–1.00) | 0.1 | 0.94 (0.92–0.97) | < 0.0001 |
ACA | 0.77 (0.4–1.5) | 0.44 | 1.17 (0.66–2.08) | 0.6 | 1.94 (1.06–3.53) | 0.03 |
ATA | 1.3 (0.86–2.01) | 0.2 | 1.03 (0.68–1.56) | 0.9 | 0.62 (0.36–1.06) | 0.08 |
ESR | 1.01 (0.99–1.02) | 0.2 | 1 (0.99–1.02) | 0.7 | 1.02 (1.01–1.03) | 0.001 |
CPI | 1.02 (1.00–1.03) | 0.008 | 1.01 (1.0–1.03) | 0.12 | 1.04 (1.03–1.06) | < 0.0001 |
dcSSc: diffuse cutaneous SSc; PH: presence of pulmonary hypertension; CPI: composite physiologic index 18; ACA: anticentromere antibodies; ATA: antitopoisomerase antibodies; FVC: forced vital capacity; FEV1: forced expiratory volume 1 second; IL: interleukin; DTPA:99mTc-technetium-labeled diethylene-triamine-pentacetate clearance; KCO: carbon monoxide transfer coefficient corrected for lung volume; ESR: erythrocyte sedimentation rate.